Clinical Trials for Non-Small Cell Lung Cancer

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with unresectable or metastatic solid tumors and homozygous MTAP gene deletions, evaluating the safety and efficacy of MRTX1719, a drug targeting PRMT5 to selectively affect tumor cells. Patients must have an ECOG performance status of 0 or 1 and participate in an open-label, multicenter study with a focus on specific tumor types in phase 2.

ClinicalTrials.gov ID: NCT05245500

Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with untreated advanced or metastatic non-squamous NSCLC, including those with an STK11 mutation, receiving bemcentinib—a selective AXL receptor tyrosine kinase inhibitor—alongside pembrolizumab, carboplatin, and pemetrexed to evaluate safety, tolerability, and antitumor activity.

ClinicalTrials.gov ID: NCT05469178

A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial investigates the safety and tolerability of TILT-123, an oncolytic adenovirus encoding TNF-alpha and IL-2, in combination with Pembrolizumab, for adult patients with non-small cell lung cancer refractory to immune checkpoint inhibitors, aiming to stimulate anti-tumor immune responses and establish the Maximum Tolerated Dose.

ClinicalTrials.gov ID: NCT06125197

Phase I/II Study Exploring the Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of the investigational drug APL-101, a selective c-MET inhibitor, with standard osimertinib therapy in adults with EGFR-mutated metastatic NSCLC, focusing on those who have been on osimertinib for 8 to 16 weeks without disease progression. The study aims to establish the maximum tolerated dose and assess progression-free survival and objective response rate.

ClinicalTrials.gov ID: NCT04743505

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 as Monotherapy and in Combination With Docetaxel in Participants With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors with SMARCA4 mutations, evaluating the investigational drug PRT3789, a novel SMARCA2 degrader, as monotherapy or combined with docetaxel. The study aims to determine the safety, tolerability, and optimal dosing, focusing on PRT3789's selective targeting mechanism to exploit synthetic lethality.

ClinicalTrials.gov ID: NCT05639751

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adults with metastatic or locally advanced MTAP-deleted thoracic tumors, including NSCLC with KRAS p.G12C mutations or brain metastases, testing AMG 193, an MTA-cooperative PRMT5 inhibitor, either alone or in combination with standard therapies like carboplatin, paclitaxel, pemetrexed, pembrolizumab, and sotorasib.

ClinicalTrials.gov ID: NCT06333951

A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, including those with platinum-resistant ovarian cancer or cutaneous squamous cell carcinoma, assessing the safety and efficacy of OR502, a monoclonal antibody targeting LILRB2 on tumor-associated macrophages, alone and with cemiplimab, an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT06090266

Phase 1b Study of ORIC-114 in Combination with Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations and evaluates the safety and efficacy of ORIC-114, a selective irreversible inhibitor targeting EGFR exon 20 mutations, in combination with amivantamab, a bispecific EGFR and MET receptor-directed antibody.

ClinicalTrials.gov ID: NCT06816992

A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 As Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with selected advanced or metastatic solid tumors, specifically those with renal cell carcinoma, cutaneous malignant melanoma, and cutaneous squamous cell carcinoma, who are eligible for immunotherapy. It investigates WTX-124, a conditionally-activated IL-2 prodrug, both as monotherapy and with pembrolizumab.

ClinicalTrials.gov ID: NCT05479812

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adults with advanced or metastatic non-squamous NSCLC, who have not received prior systemic treatment and exhibit no actionable genomic alterations, assessing the combination of Telisotuzumab Adizutecan, a MET-targeting agent that delivers a topoisomerase inhibitor, and Budigalimab, a PD-1 inhibitor.

ClinicalTrials.gov ID: NCT06772623